83 related articles for article (PubMed ID: 9399643)
1. SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway.
Walsh AB; Dhanasekaran M; Bar-Sagi D; Kumar CC
Oncogene; 1997 Nov; 15(21):2553-60. PubMed ID: 9399643
[TBL] [Abstract][Full Text] [Related]
2. SCH 51344 inhibits ras transformation by a novel mechanism.
Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
[TBL] [Abstract][Full Text] [Related]
3. [Inhibition of RAS-transformation by SCH51344].
Kumar CC
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1503-11. PubMed ID: 9309148
[TBL] [Abstract][Full Text] [Related]
4. SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway.
Kumar CC; Ohashi K; Nagata K; Walsh A; Bar-Sagi D; Mizuno K
Ann N Y Acad Sci; 1999; 886():122-31. PubMed ID: 10667210
[TBL] [Abstract][Full Text] [Related]
5. A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells.
Xiao L; Lang W
Cancer Res; 2000 Jan; 60(2):400-8. PubMed ID: 10667594
[TBL] [Abstract][Full Text] [Related]
6. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
7. Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells.
Futamura M; Kamiya S; Tsukamoto M; Hirano A; Monden Y; Arakawa H; Nishimura S
Oncogene; 2001 Oct; 20(46):6724-30. PubMed ID: 11709707
[TBL] [Abstract][Full Text] [Related]
8. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.
Grana TM; Rusyn EV; Zhou H; Sartor CI; Cox AD
Cancer Res; 2002 Jul; 62(14):4142-50. PubMed ID: 12124353
[TBL] [Abstract][Full Text] [Related]
9. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
10. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor.
York RD; Yao H; Dillon T; Ellig CL; Eckert SP; McCleskey EW; Stork PJ
Nature; 1998 Apr; 392(6676):622-6. PubMed ID: 9560161
[TBL] [Abstract][Full Text] [Related]
11. Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth.
Murphy GA; Solski PA; Jillian SA; Pérez de la Ossa P; D'Eustachio P; Der CJ; Rush MG
Oncogene; 1999 Jul; 18(26):3831-45. PubMed ID: 10445846
[TBL] [Abstract][Full Text] [Related]
12. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells.
Ulkü AS; Schäfer R; Der CJ
Mol Cancer Res; 2003 Dec; 1(14):1077-88. PubMed ID: 14707291
[TBL] [Abstract][Full Text] [Related]
13. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
14. TC21 and Ras share indistinguishable transforming and differentiating activities.
Graham SM; Oldham SM; Martin CB; Drugan JK; Zohn IE; Campbell S; Der CJ
Oncogene; 1999 Mar; 18(12):2107-16. PubMed ID: 10321735
[TBL] [Abstract][Full Text] [Related]
15. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism.
Lambert JM; Lambert QT; Reuther GW; Malliri A; Siderovski DP; Sondek J; Collard JG; Der CJ
Nat Cell Biol; 2002 Aug; 4(8):621-5. PubMed ID: 12134164
[TBL] [Abstract][Full Text] [Related]
16. An essential role for Rac in Ras transformation.
Qiu RG; Chen J; Kirn D; McCormick F; Symons M
Nature; 1995 Mar; 374(6521):457-9. PubMed ID: 7700355
[TBL] [Abstract][Full Text] [Related]
17. Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation.
Zohar M; Teramoto H; Katz BZ; Yamada KM; Gutkind JS
Oncogene; 1998 Aug; 17(8):991-8. PubMed ID: 9747878
[TBL] [Abstract][Full Text] [Related]
18. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts.
Tang Y; Chen Z; Ambrose D; Liu J; Gibbs JB; Chernoff J; Field J
Mol Cell Biol; 1997 Aug; 17(8):4454-64. PubMed ID: 9234703
[TBL] [Abstract][Full Text] [Related]
19. Rac is required for v-Abl tyrosine kinase to activate mitogenesis.
Renshaw MW; Lea-Chou E; Wang JY
Curr Biol; 1996 Jan; 6(1):76-83. PubMed ID: 8805224
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Ras-induced cancers by the F-actin cappers tensin and chaetoglobosin K, in combination with the caspase-1 inhibitor N1445.
Tikoo A; Cutler H; Lo SH; Chen LB; Maruta H
Cancer J Sci Am; 1999; 5(5):293-300. PubMed ID: 10526670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
